Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDKN2C
REST API REST API
Homo sapiens
CDKN2C is differentially expressed in 341 experiments: 138 organism parts: bone marrow, thymus, ... (136 more);, 212 disease states: normal, glioblastoma, ... (210 more);, 109 cell types 496 cell lines 56 compound treatments and 81 other conditions.
Synonyms p18, INK4C
Orthologs Cdkn2c (Mus musculus)   A7MBB9_BOVIN (Bos taurus)   CDKN2C (Danio rerio)   CDKN2C (Gallus gallus)   Cdkn2c (Rattus norvegicus)   NP_001116932.1 (Xenopus laevis)   CDKN2C (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, negative regulation of cell growth, protein binding, cytoplasm, negative regulation of cell proliferation, mitotic cell cycle, regulation of cyclin-dependent protein kinase activity, cell cycle arrest, G1 phase of mitotic cell cycle, induction of apoptosis, protein kinase binding, G1/S transition of mitotic cell cycle, nucleus, cyclin-dependent protein kinase inhibitor activity, oligodendrocyte differentiation, negative regulation of phosphorylation
InterPro Term Ankyrin_rpt, Ankyrin_rpt-contain_dom
UniProt Accession Q6ICV4, Q9P1T2, P42773
Search EB-eye ENSG00000123080
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
Jurkat
2
E-GEOD-1880, E-MTAB-62
AGS
2
E-MTAB-37, E-GEOD-15460
MOLT4
2
E-MTAB-62, E-MTAB-37
T84
2
E-MTAB-37, E-GEOD-1474
490 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (56 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
2
2
E-TABM-130, E-TABM-145
fibroblast
2
E-GEOD-3204, E-GEOD-3920
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
macrophage
1
2
E-GEOD-22373, E-GEOD-360, E-GEOD-8286
leydig cell
1
E-MTAB-25
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-MTAB-62, E-GEOD-5418, ... (62 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-GEOD-6014, E-MTAB-62, E-GEOD-4412
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-995, E-GEOD-96
control
3
E-GEOD-16363, E-GEOD-8121, E-GEOD-20602
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
prostate carcinoma
3
E-MEXP-2034, E-GEOD-96, E-MTAB-62
leiomyosarcoma
2
E-MTAB-62, E-GEOD-6481
206 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, ... (32 experiments)

Factor Value U/D Experiments
none
6
8
E-GEOD-5824, E-GEOD-412, E-GEOD-995, E-GEOD-6431, E-GEOD-20719, ... (14 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
bacterial endotoxin
1
E-GEOD-3284
control
1
E-GEOD-3284
neocarzinostatin
1
E-GEOD-1676
control for EGF
1
E-GEOD-6462
50 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-20499, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MEXP-2283, ... (6 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-2509, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-10315, E-TABM-440, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-1956, E-MEXP-2069, ... (35 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-923 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, ... (12 experiments)

Population
studied in E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-TABM-43, E-GEOD-4922, ... (6 experiments)

Processing time: 0.27 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM